NCT05932290View on ClinicalTrials.gov

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

CompletedOBSERVATIONAL
Enrollment

514

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

July 12, 2023

Study Completion Date

July 12, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

Elranatamab

BCMA-CD3 bispecific antibody

DRUG

Standard of care

Standard of care

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY